{"disease":{"id":"prevention-of-venous-thromboembolism","name":"Prevention of venous thromboembolism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"xarelto","indication_name":"Prevention of venous thromboembolism from re-occuring","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Prevention of venous thromboembolism in undergoing surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin-sodium","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"rivaroxaban","indication_name":"Prevention of venous thromboembolism from re-occuring","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Prevention of venous thromboembolism in undergoing surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"lovenox","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin","indication_name":"Prevention of venous thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04267718","title":"Efficacy of the Use of Risk Scores in Reducing Important Clinical Outcomes in Hospitalized Medical Ill Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":2878,"lead_sponsor_name":"Fadoi Foundation, Italy","has_results":false},{"nct_id":"NCT03055026","title":"Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":582,"lead_sponsor_name":"Fadoi Foundation, Italy","has_results":false},{"nct_id":"NCT05752461","title":"SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Beijing Suncadia Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06193863","title":"An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"Bayer","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}